Abstract
Until recently, inflammatory chemokines were viewed mainly as indispensable “gate keepers” of immunity and inflammation. However, updated research indicates that members of this chemokine sub-family are important constituents of the tumor microenvironment, having multifaceted tumor-promoting roles in cancer. A very large number of studies indicate that many of the inflammatory chemokines are exploited by the tumor cells for their own benefit, and are actually skewed to the pro-malignancy phenotype. The different chemokines may be simultaneously expressed at the tumor site, having overlapping but also distinct tumor-promoting impacts. In general (except for the axis of CXCR3 and its ligands, that acts as a “double-edged sword”), the inflammatory chemokines induce immune imbalance at primary tumors and metastatic sites, doing so by promoting the presence and activation of tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC) and/or T regulatory cells (Treg). In parallel, immune suppression is ensued due to inhibition of Th1 cells and cytotoxic T lymphocytes (CTL). The chemokines also elevate metastasis-related processes, such as angiogenesis and osteoclastogenesis in the bone. Furthermore, they act directly on the tumor cells, promoting their proliferation, migration and invasion properties. Obviously, not all chemokines have the same pro-malignancy roles; however, chemokines that share the same receptor tend to have much in common in terms of their pro-cancerous activities. Accordingly, we will describe the roles of inflammatory chemokines in malignancy by using a receptor-based categorization: (1) CXCR1 and CXCR2 with their ELR+ CXC chemokine ligands, primarily CXCL8 (IL-8) but also CXCL1 (MGSA, GROα) and CXCL5 (ENA-78); (2) CXCR3 with its non-ELR CXC chemokine ligands: CXCL9 (Mig), CXCL10 (IP-10) and CXCL11 (I-Tac); (3) CCR2 and its ligands, mainly CCL2 (MCP-1); (4) CCR5 and its corresponding chemokines, with major emphasis on CCL5 (RANTES) and CCL3 (MIP-1α). Based on the findings obtained so far, we propose that inflammatory chemokines and their receptors are attractive therapeutic targets in malignancy, and discuss the expected difficulties in translating such approaches in the clinic.
Yaeli Lebel-Haziv, Shalom Lerrer, Polina Weitzenfeld are equal contributors to this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Acharyya S, Oskarsson T, Vanharanta S et al (2012) A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis. Cell 150:165–178
Acosta JC, Gil J (2009) A role for CXCR2 in senescence, but what about in cancer? Cancer Res 69:2167–2170
Acosta JC, O’Loghlen A, Banito A et al (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133:1006–1018
Addison CL, Daniel TO, Burdick MD et al (2000) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165:5269–5277
Adler EP, Lemken CA, Katchen NS, Kurt RA (2003) A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 90:187–194
Agarwal A, Tressel SL, Kaimal R et al (2010) Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 70:5880–5890
Aldinucci D, Lorenzon D, Cattaruzza L et al (2008) Expression of CCR5 receptors on reed-sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 122:769–776
Ali S, Kaur J, Patel KD (2000) Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 157:313–321
Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66:1–9
Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787–820
Andersson A, Srivastava MK, Harris-White M et al (2011) Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res 17:3660–3672
Amatschek S, Lucas R, Eger A et al (2010) CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer 104:469–479
Andersson A, Yang SC, Huang M et al (2009) IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 182:6951–6958
Araki K, Shimura T, Yajima T et al (2009) Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem 284:32305–32311
Azenshtein E, Luboshits G, Shina S et al (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of premalignant activity. Cancer Res 62:1093–1102
Baba T, Badr Mel S, Tomaru U, Ishizu A, Mukaida N (2012) Novel process of Intrathymic tumor-immune tolerance through CCR2-mediated recruitment of Sirpalpha(+) dendritic cells: a murine model. PLoS One 7:e41154
Balkwill FR, Mantovani A (2011) Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22:33–40
Bandapalli OR, Ehrmann F, Ehemann V et al (2012) Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine 57:46–53
Bates RC, DeLeo MJ 3rd, Mercurio AM (2004) The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 299:315–324
Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52
Ben-Baruch A (2007) Expert commentary: the chemokine receptor CXCR3 and its ligands in malignancy: do they act as double edged swords? In: Grinwald LR (ed) Chemokine research trends. Nova Science Publishers, Inc, New York, pp 1–6
Ben-Baruch A (2012a) The inflammatory CC chemokines CCL2 and CCL5 in malignancy: leukocyte migration and beyond. In: Ben-Baruch A (ed) The inflammatory milieu of tumors: cytokines and chemokines that affect tumor growth and metastasis, Bentham Science Publishers, pp 99–114
Ben-Baruch A (2012b) The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory axis of TNF alpha and chemokines. Cancer Microenviron 5:151–164
Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28–37
Bendrik C, Dabrosin C (2009) Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol 182:371–378
Benoy IH, Salgado R, Van Dam P et al (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10:7157–7162
Berencsi K, Rani P, Zhang T et al (2011) In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med 9:33
Bhatt RS, Wang X, Zhang L et al (2010) Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 9:2793–2802
Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889–896
Bonavia R, Inda MM, Vandenberg S et al (2012) EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene 4054–4066
Borczuk AC, Papanikolaou N, Toonkel RL et al (2008) Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene 27:557–564
Bronger H, Kraeft S, Schwarz-Boeger U et al (2012) Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res 14:R30
Burns JM, Summers BC, Wang Y et al (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203:2201–2213
Bussard KM, Okita N, Sharkey N, Neuberger T, Webb A, Mastro AM (2010a) Localization of osteoblast inflammatory cytokines MCP-1 and VEGF to the matrix of the trabecula of the femur, a target area for metastatic breast cancer cell colonization. Clin Exp Metastasis 27:331–340
Bussard KM, Venzon DJ, Mastro AM (2010b) Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J Cell Biochem 111:1138–1148
Cambien B, Richard-Fiardo P, Karimdjee BF et al (2011) CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFR beta in colorectal carcinoma. PLoS One 6:e28842
Cambien B, Karimdjee BF, Richard-Fiardo P et al (2009) Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 100:1755–1764
Campanella GS, Colvin RA, Luster AD (2010) CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One 5:e12700
Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE (2007) Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8:70–76
Cataisson C, Ohman R, Patel G et al (2009) Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res 69:319–328
Chang LY, Lin YC, Mahalingam J et al (2012a) Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 72:1092–1102
Chang LY, Lin YC, Kang CW et al (2012b) The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103 + effector/memory regulatory T cells. J Immunol 189:567–574
Chen YC, Sosnoski DM, Gandhi UH, Novinger LJ, Prabhu KS, Mastro AM (2009) Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer. Carcinogenesis 30:1941–1948
Chen Y, Chen L, Li JY et al (2011) ERbeta and PEA3 co-activate IL-8 expression and promote the invasion of breast cancer cells. Cancer Biol Ther 11:497–511
Chiu HY, Sun KH, Chen SY et al (2012) Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells. Cytokine 59:423–432
Chuang JY, Yang WH, Chen HT et al (2009) CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol 220:418–426
Conti I, Rollins BJ (2004) CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 14:149–154
Cortez-Retamozo V, Etzrodt M, Newton A et al (2012) Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 109:2491–2496
Craig MJ, Loberg RD (2006) CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev 25:611–619
Dairaghi DJ, Oyajobi BO, Gupta A et al (2012) CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 1449–1457
Datta D, Banerjee P, Gasser M, Waaga-Gasser AM, Pal S (2010) CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem 285:36842–36848
Datta D, Flaxenburg JA, Laxmanan S et al (2006) Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 66:9509–9518
Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S (2008) Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol 19:2437–2446
De Larco JE, Wuertz BR, Rosner KA et al (2001) A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158:639–646
De Larco JE, Wuertz BR, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10:4895–4900
Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313–326
Dhawan P, Richmond A (2002) Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 72:9–18
Diaz-Valdes N, Basagoiti M, Dotor J et al (2011) Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 71:812–821
Dimberg J, Strom K, Lofgren S, Zar N, Lindh M, Matussek A (2012) DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas. Int J Colorectal Dis 27:709–714
Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM (2004) Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 173:6234–6240
Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C (2011) IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 71:5296–5306
Fontemaggi G, Dell’Orso S, Trisciuoglio D et al (2009) The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16:1086–1093
Freund A, Chauveau C, Brouillet JP et al (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22:256–265
Fridlender ZG, Sun J, Kim S et al (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16:183–194
Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33:949–955
Fridlender ZG, Kapoor V, Buchlis G et al (2011) Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 44:230–237
Fritz EA, Glant TT, Vermes C, Jacobs JJ, Roebuck KA (2002) Titanium particles induce the immediate early stress responsive chemokines IL-8 and MCP-1 in osteoblasts. J Orthop Res 20:490–498
Fujihara A, Kurooka M, Miki T, Kaneda Y (2008) Intratumoral injection of inactivated sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 57:73–84
Fujimoto H, Sangai T, Ishii G et al (2009) Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125:1276–1284
Fujita M, Zhu X, Ueda R et al (2009) Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells–significant roles of CXCL10. Cancer Res 69:1587–1595
Fulton AM (2009) The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 11:125–131
Gabellini C, Trisciuoglio D, Desideri M et al (2009) Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer 45:2618–2627
Gacci M, Serni S, Lapini A et al (2009) CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma. J Urol 181:843–848
Gallo M, De Luca A, Lamura L, Normanno N (2012) Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 23:597–604
Gehad AE, Lichtman MK, Schmults CD et al (2012) Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Invest Dermatol
Ginestier C, Liu S, Diebel ME et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485–497
Goede V, Brogelli L, Ziche M, Augustin HG (1999) Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 82:765–770
Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S (2011) Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 71:5455–5466
Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R (2011) Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20:300–314
Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:937–941
Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71:2411–2416
Grepin R, Guyot M, Jacquin M et al (2011) Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene 31:1683–1694
Greten TF, Manns MP, Korangy F (2011) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11:802–807
Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89:207–215
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–74
Hagemann T, Balkwill F, Lawrence T (2007) Inflammation and cancer: a double-edged sword. Cancer Cell 12:300–301
Haghnegahdar H, Du J, Wang D et al (2000) The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol 67:53–62
Haim K, Weitzenfeld P, Meshel T, Ben-Baruch A (2011) Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Neoplasia 13:230–243
Halpern JL, Kilbarger A, Lynch CC (2011) Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett 308:91–99
Hart KM, Bak SP, Alonso A, Berwin B (2009) Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer. Neoplasia 11:564–573, 1 p following 73
Hong M, Puaux AL, Huang C et al (2011) Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 71:6997–7009
Hu H, Sun L, Guo C et al (2009) Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res 15:5485–5493
Huang D, Ding Y, Zhou M et al (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063–1071
Huang S, Singh RK, Xie K et al (1994) Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 39:231–238
Huang B, Lei Z, Zhao J et al (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252:86–92
Huh SJ, Liang S, Sharma A, Dong C, Robertson GP (2010) Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res 70:6071–6082
Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM (2012) CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol 18:1249–1256
Hwang WL, Yang MH, Tsai ML et al (2011) SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 141:279–291, 91 e1–5
Ijichi H, Chytil A, Gorska AE et al (2011) Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 121:4106–4117
Ijichi H (2012) Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer. Oncoimmunology 1:569–71
Inoue H, Iga M, Xin M et al (2008) TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother 57:1399–1411
Izhak L, Wildbaum G, Jung S, Stein A, Shaked Y, Karin N (2012) Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS One 7:e28305
Izhak L, Wildbaum G, Weinberg U et al (2010) Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J Immunol 184:1092–1101
Jin G, Kawsar HI, Hirsch SA et al (2010) An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One 5:e10993
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252
Ju D, Sun D, Xiu L, Meng X, Zhang C, Wei P (2012) Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells. Med Oncol 29:91–99
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401
Karnoub AE, Dash AB, Vo AP et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557–563
Kawai Y, Kaidoh M, Yokoyama Y, Sano K, Ohhashi T (2009) Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. Cancer Sci 100:419–428
Keeley EC, Mehrad B, Strieter RM (2008) Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 28:1928–1936
Keeley EC, Mehrad B, Strieter RM (2010) CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106:91–111
Keklikoglou I, Koerner C, Schmidt C et al (2012) MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 31:4150–4163
Kim S, Lewis C, Nadel JA (2011) Epidermal growth factor receptor reactivation induced by E-prostanoid-3 receptor- and tumor necrosis factor-alpha-converting enzyme-dependent feedback exaggerates interleukin-8 production in airway cancer (NCI-H292) cells. Exp Cell Res 317:2650–2660
Kinder M, Chislock E, Bussard KM, Shuman L, Mastro AM (2008) Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 314:173–183
Knowles LM, Stabile LP, Egloff AM et al (2009) HGF and c-met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 15:3740–3750
Koga M, Kai H, Egami K et al (2008) Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 365:279–284
Kreeger PK, Mandhana R, Alford SK, Haigis KM, Lauffenburger DA (2009) RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res 69:8191–8199
Kuai WX, Wang Q, Yang XZ, Zhao Y, Yu R, Tang XJ (2012) Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol 18:979–985
Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173:310–317
Lapteva N, Huang XF (2010) CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther 10:725–733
Lasagni L, Francalanci M, Annunziato F et al (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197:1537–1549
Laubli H, Spanaus KS, Borsig L (2009) Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 114:4583–4591
Lee CY, Huang CY, Chen MY, Lin CY, Hsu HC, Tang CH (2011) IL-8 increases integrin expression and cell motility in human chondrosarcoma cells. J Cell Biochem 112:2549–2557
Lee JH, Kim HN, Kim KO et al (2012a) CXCL10 promotes osteolytic Bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Cancer Res 72:3175–3186
Lee Y, Chittezhath M, Andre V et al (2012b) Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood 119:227–237
Leibovich-Rivkin T, Buganim Y, Solomon H, Meshel T, Rotter V, Ben-Baruch A (2012) Tumor-promoting circuits that regulate a cancer-related chemokine cluster: Dominanc eof inflammatory mediators over oncogenic alerations. Cancers 4:55–76
Lesokhin AM, Hohl TM, Kitano S et al (2012) Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72:876–886
Leuschner F, Dutta P, Gorbatov R et al (2011) Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29:1005–1010
Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 3:e3077
Levy JA (2009) The unexpected pleiotropic activities of RANTES. J Immunol 182:3945–3946
Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK (2005) Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8:63–71
Li M, Zhang Y, Feurino LW et al (2008) Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci 99:733–737
Li X, Sterling JA, Fan KH et al (2012) Loss of TGF-beta responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res 10:494–503
Lin Y, Huang R, Chen L et al (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109:507–515
Liu C, Luo D, Reynolds BA et al (2011) Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis 32:129–137
Lu X, Kang Y (2009) Chemokine (C-C motif) ligand 2 engages CCR2 + stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284:29087–29096
Luan J, Shattuck-Brandt R, Haghnegahdar H et al (1997) Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 62:588–597
Luboshits G, Shina S, Kaplan O et al (1999) Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59:4681–4687
Ma X, Norsworthy K, Kundu N et al (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8:490–498
Makinoshima H, Dezawa M (2009) Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway. FEBS Lett 583:3697–3703
Manome Y, Wen PY, Hershowitz A et al (1995) Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother 41:227–235
Mantovani A, Bonecchi R, Locati M (2006) Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6:907–918
Martin D, Galisteo R, Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284:6038–6042
Matsuo Y, Raimondo M, Woodward TA et al (2009) CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 125:1027–1037
Merritt WM, Lin YG, Spannuth WA et al (2008) Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100:359–372
Mestdagt M, Polette M, Buttice G et al (2006) Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer 118:35–42
Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC (2011) Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 32:477–487
Mishra P, Banerjee D, Ben-Baruch A (2011) Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 89:31–39
Mizutani K, Sud S, McGregor NA et al (2009) The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11:1235–1242
Molloy AP, Martin FT, Dwyer RM et al (2009) Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 124:326–332
Molon B, Ugel S, Del Pozzo F et al (2011) Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 208:1949–1962
Mueller A, Strange PG (2004) The chemokine receptor, CCR5. Int J Biochem Cell Biol 36:35–38
Murakami T, Kawada K, Iwamoto M et al (2013) The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 276–287
Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618–631
Murooka TT, Rahbar R, Fish EN (2009) CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 387:381–386
Muthuswamy R, Berk E, Junecko BF et al (2012) NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 3735–3743
Nakasone ES, Askautrud HA, Kees T et al (2012) Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21:488–503
Nam JS, Kang MJ, Suchar AM et al (2006) Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66:7176–7184
Naldini A, Filippi I, Miglietta D, Moschetta M, Giavazzi R, Carraro F (2010) Interleukin-1beta regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1alpha. Eur J Cancer 46:3400–3408
Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nor JE (2009) Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 11:583–593
Nesbeth Y, Scarlett U, Cubillos-Ruiz J et al (2009) CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 69:6331–6338
Nesbeth YC, Martinez DG, Toraya S et al (2010) CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol 184:5654–5662
Neumark E, Cohn MA, Lukanidin E, Witz IP, Ben-Baruch A (2002) Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunol Lett 82:111–121
Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP (2003) Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and ant malignancy factors. Int J Cancer 106:879–886
Nieman KM, Kenny HA, Penicka CV et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498–1503
Ning Y, Labonte MJ, Zhang W et al (2012) The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther 11:1353–1364
Ning Y, Manegold PC, Hong YK, et al (2011) Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 128:2038–2049
Niu J, Azfer A, Zhelyabovska O, Fatma S, Kolattukudy PE (2008) Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem 283:14542–14551
O’Hayer KM, Brady DC, Counter CM (2009) ELR+ CXC chemokines and oncogenic ras-mediated tumorigenesis. Carcinogenesis 30:1841–1847
Oppermann M (2004) Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 16:1201–1210
Pahler JC, Tazzyman S, Erez N et al (2008) Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10:329–340
Pantschenko AG, Pushkar I, Miller LJ et al (2003) In vitro demonstration of breast cancer tumor cell sub-populations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 10:1011–1017
Park SI, Liao J, Berry JE et al (2012) Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res 72:2522–2532
Pathi SP, Kowalczewski C, Tadipatri R, Fischbach C (2010) A novel 3-D mineralized tumor model to study breast cancer bone metastasis. PLoS One 5:e8849
Petrai I, Rombouts K, Lasagni L et al (2008) Activation of p38 (MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 40:1764–1774
Piccard H, Muschel RJ, Opdenakker G (2012) On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 82:296–309
Pinilla S, Alt E, Abdul Khalek FJ et al (2009) Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 284:80–85
Popivanova BK, Kostadinova FI, Furuichi K et al (2009) Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69:7884–7892
Pradelli E, Karimdjee-Soilihi B, Michiels JF et al (2009) Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 125:2586–2594
Przewoznik M, Homberg N, Naujoks M et al (2012) Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer. J Immunother 35:217–222
Qian BZ, Li J, Zhang H et al (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:222–225
Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63:8360–8365
Rody A, Karn T, Liedtke C, et al (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13:R97
Rollins BJ, Sunday ME (1991) Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 11:3125–3131
Rolny C, Capparuccia L, Casazza A et al (2008) The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 205:1155–1171
Roy A, Kolattukudy PE (2012) Monocyte chemotactic protein-induced protein (MCPIP) promotes inflammatory angiogenesis via sequential induction of oxidative stress, endoplasmic reticulum stress and autophagy. Cell Signal 24:2123–2131
Ruan JW, Liao YC, Lua I, Li MH, Hsu CY, Chen JH (2012) Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells. Breast Cancer Res 14:R106
Salcedo R, Ponce ML, Young HA et al (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34–40
Salcedo R, Martins-Green M, Gertz B, Oppenheim JJ, Murphy WJ (2002) Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clin Cancer Res 8:2655–2665
Schaer DA, Lesokhin AM, Wolchok JD (2011) Hiding the road signs that lead to tumor immunity. J Exp Med 208:1937–1940
Seeger H, Wallwiener D, Mueck AO (2006) Different effects of estradiol and various antiestrogens on TNF-alpha-induced changes of biochemical markers for growth and invasion of human breast cancer cells. Life Sci 78:1464–1468
Seeger H, Wallwiener D, Mueck AO (2008) Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol 24:576–579
Shamaladevi N, Lyn DA, Escudero DO, Lokeshwar BL (2009) CXC receptor-1 silencing inhibits androgen-independent prostate cancer. Cancer Res 69:8265–8274
Shimoda M, Mellody KT, Orimo A (2010) Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol 21:19–25
Shin SY, Hyun J, Lim Y, Lee YH (2011) 3’-Chloro-5, 7-dimethoxyisoflavone inhibits TNFalpha-induced CXCL10 gene transcription by suppressing the NF-kappaB pathway in HCT116 human colon cancer cells. Int Immunopharmacol 11:2104–2111
Singh RK, Lokeshwar BL (2009) Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 8:57
Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK (2009a) CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 100:1638–1646
Singh S, Sadanandam A, Nannuru KC et al (2009b) Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 15:2380–2386
Singh S, Varney M, Singh RK (2009c) Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 69:411–415
Singh S, Singh AP, Sharma B, Owen LB, Singh RK (2010a) CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol 6:111–6
Singh S, Sadanandam A, Varney ML, Nannuru KC, Singh RK (2010b) Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion. Int J Cancer 126:328–336
Snoussi K, Mahfoudh W, Bouaouina N et al (2010) Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 10:283
Song JK, Park MH, Choi DY et al (2012) Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS One 7:e33747
Song S, Liu C, Wang J et al (2009) Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine 27:1111–1118
Soria G (2009) AB-B the CCL5/CCR5 axis in cancer. In: Fulton A (ed) Chemokine receptors in cancer, Humana Press, New York
Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267:271–285
Soria G, Yaal-Hahoshen N, Azenshtein E et al (2008) Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 44:191–200
Soria G, Lebel-Haziv Y, Ehrlich M et al (2012) Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5’s 40s loop and intracellular glycosaminoglycans. Neoplasia 14:1–19
Soria G, Ofri-Shahak M, Haas I et al (2011) Inflammatory mediators in breast cancer: coordinated expression of TNFalpha and IL-1beta with CCL2 and CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11:130
Strell C, Lang K, Niggemann B, Zaenker KS, Entschladen F (2010) Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp Cell Res 316:138–148
Stathopoulos GT, Psallidas I, Moustaki A et al (2008) A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 100:1464–1476
Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184:1630–1641
Suffee N, Hlawaty H, Meddahi-Pelle A et al (2012) RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 727–744
Suffee N, Richard B, Hlawaty H, Oudar O, Charnaux N, Sutton A (2011) Angiogenic properties of the chemokine RANTES/CCL5. Biochem Soc Trans 39:1649–1653
Sugasawa H, Ichikura T, Kinoshita M et al (2008a) Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 122:2535–2541
Sugasawa H, Ichikura T, Tsujimoto H et al (2008b) Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol 97:445–450
Sunaga N, Imai H, Shimizu K et al (2012) Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 130:1733–1744
Tan MC, Goedegebuure PS, Belt BA et al (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182:1746–1755
Tanese K, Grimm EA, Ekmekcioglu S (2012) The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer 131:891–901
Tang CH, Tsai CC (2012b) CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochem Pharmacol 83:335–344
Tang KH, Ma S, Lee TK et al (2012b) CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55:807–820
Tjomsland V, Spangeus A, Valila J et al (2011) Interleukin 1alpha sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13:664–675
Tsuchiyama T, Nakamoto Y, Sakai Y, Mukaida N, Kaneko S (2008) Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Cancer Sci 99:2075–2082
Tsuyada A, Chow A, Wu J et al (2012) CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 72:2768–2779
Ueno T, Toi M, Saji H et al (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6:3282–3289
Umemura N, Saio M, Suwa T et al (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83:1136–1144
Vallet S, Pozzi S, Patel K et al (2011) A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 25:1174–1181
Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267:226–244
Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R, Singh RK (2011) Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett; 300: 180–188.
Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71:2550–2560
Velasco-Velazquez M, Jiao X, De La Fuente M et al (2012) CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 3839–3850
Verma R, Bowen RL, Slater SE, Mihaimeed F, Jones JL (2012) Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. Br Med Bull 129–145
Walser TC, Rifat S, Ma X et al (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 66:7701–7707
Wang P, Yang X, Xu W, Li K, Chu Y, Xiong S (2011) Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother 59:1715–1726
Wang S, Xu M, Li F et al (2012a) Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1. Breast Cancer Res Treat 133:1037–1048
Wang SW, Wu HH, Liu SC et al (2012b) CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One 7:e35101
Wang Y, Xu RC, Zhang XL et al (2012c) Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 59:145–155
Warner KA, Miyazawa M, Cordeiro MM et al (2008) Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia 10:131–139
Wasmuth JC, Rockstroh JK, Hardy WD (2012) Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opin Drug Saf 11:161–174
Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735–6741
Weber KS, Nelson PJ, Grone HJ, Weber C (1999) Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 19:2085–2093
Welte G, Alt E, Devarajan E, Krishnappa S, Jotzu C, Song YH (2012) Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasion. Mol Carcinog
Wendel M, Galani IE, Suri-Payer E, Cerwenka A (2008) Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68:8437–8445
Wigler N, Shina S, Kaplan O et al (2002) Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease. Isr Med Assoc J 4:940–943
Wilson TJ, Nannuru KC, Futakuchi M, Singh RK (2010) Cathepsin G-mediated enhanced TGF-beta signaling promotes angiogenesis via upregulation of VEGF and MCP-1. Cancer Lett 288:162–169
Winkler AE, Brotman JJ, Pittman ME et al (2011) CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis. Cancer Res 71:5707–5716
Wolf MJ, Hoos A, Bauer J et al (2012) Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22:91–105
Wright KM, Friedland JS (2004) Regulation of chemokine gene expression and secretion in staphylococcus aureus-infected osteoblasts. Microbes Infect 6:844–852
Wu Y, Li YY, Matsushima K, Baba T, Mukaida N (2008a) CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol 181:6384–6393
Wu FY, Ou ZL, Feng LY et al (2008b) Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res 6:1276–1288
Xu J, Zhang C, He Y et al (2012) Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer 130:787–797
Yang J, Richmond A (2004) The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 9:846–855
Yang J, Wang Y, Gao Y, Shao J, Zhang XJ, Yao Z (2009) Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine 46:382–391
Yang G, Rosen DG, Liu G et al (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16:3875–3886
Yaal-Hahoshen N, Shina S, Leider-Trejo L et al (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12:4474–4480
Yadav A, Saini V, Arora S (2010) MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411:1570–1579
Yamamoto M, Kikuchi H, Ohta M et al (2008) TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res 68:9754–9762
Yeudall WA, Vaughan CA, Miyazaki H et al (2012) Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33:442–451
Yokoe T, Iino Y, Takei H et al (1997) Changes of cytokines and thyroid function in patients with recurrent breast cancer. Anticancer Res 17:695–699
Yoo JY, Kim JH, Kim J et al (2008) Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 15:635–651
Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40:2969–2975
Youngs SJ, Ali SA, Taub DD, Rees RC (1997) Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 71:257–266
Zhang X, Haney KM, Richardson AC et al (2010) Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. Bioorg Med Chem Lett 20:4627–4630
Zhang Y, Yao F, Yao X et al (2009) Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 21:1113–1121
Zhong L, Roybal J, Chaerkady R et al (2008) Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 68:7237–7245
Zhu X, Fallert-Junecko BA, Fujita M et al (2010) Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 59:1401–1409
Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L (2007) EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 282:26656–26664
Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243
Zuccari DA, Leonel C, Castro R, et al (2012) An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem 114:571–576
Acknowledgments
The authors thank the following organizations for supporting the studies related to this review, performed in Dr. Ben-Baruch’s laboratory: Israel Science Foundation, The Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ) and Israel’s Ministry of Science and Technology (MOST), Israel Ministry of Health, Israeli Cancer Association and Federico Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Leibovich-Rivkin, T., Lebel-Haziv, Y., Lerrer, S., Weitzenfeld, P., Ben-Baruch, A. (2013). The Versatile World of Inflammatory Chemokines in Cancer. In: Shurin, M., Umansky, V., Malyguine, A. (eds) The Tumor Immunoenvironment. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6217-6_6
Download citation
DOI: https://doi.org/10.1007/978-94-007-6217-6_6
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6216-9
Online ISBN: 978-94-007-6217-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)